Onkologie. 2020:14(2):85-87 | DOI: 10.36290/xon.2020.015

Prenatal and postnatal management of children exposed to cancer treatment in utero

Vít Drochýtek
Gynekologicko-porodnická klinika FNKV a 3. LF UK v Praze

Malignancy diagnosed during pregnancy poses a threat to both maternal and fetal life. For the vast majority of patients pregnancy itself does not worsen their prognosis. When considering cancer treatment in pregnancy we avoid jeopardizing patients' survival by delay of treatment while simultaneously aiming for on-term delivery since prematurity is a major driver of neonatal mortality and morbidity. Thanks to growing evidence regarding the safety of such treatment more children are exposed to cancer treatment in utero. Administration of chemotherapy, in particular, requires careful fetal surveillance and optimal obstetric management. Despite the generally good outcome of these children, postnatal follow-up till adulthood is recommended.

Keywords: pregnancy, chemotherapy, flowmetry, prematurity, neurocognitive development.

Published: June 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Drochýtek V. Prenatal and postnatal management of children exposed to cancer treatment in utero. Onkologie. 2020;14(2):85-87. doi: 10.36290/xon.2020.015.
Download citation

References

  1. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283-291. Go to original source... Go to PubMed...
  2. Pentheroudakis G, Pavlidis N. Cancer and pregnancy: poena magna, not anymore. Eur J Cancer 2006; 42: 126-140. Go to original source... Go to PubMed...
  3. Calsteren KV, Verbesselt R, Devlieger R, et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastuzumab in a baboon model. Int J Gynecol Cancer 2010; 20: 1456-1464. Go to PubMed...
  4. de Haan J, Verheecke M, Van Calsteren K, et al. Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients. Lancet Oncol 2018; 19: 337-346. Go to original source... Go to PubMed...
  5. Calsteren KV, Verbesselt R, Beijnen J, et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxycyclophosphamide in a baboon model. Gynecol Oncol 2010; 119: 594-600. Go to original source... Go to PubMed...
  6. Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med 2015; 373: 1824-1834. Go to original source... Go to PubMed...
  7. Amant F, Van Calsteren K, Halaska MJ, et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol 2012; 13: 256-264. Go to original source... Go to PubMed...
  8. Avilés A, Neri N, Nambo MJ. Long-term evaluation of cardiac function in children who received anthracyclines during pregnancy. Ann Oncol 2006; 17: 286-288. Go to original source... Go to PubMed...
  9. Avilés A, Neri N. Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2001; 2: 173-177. Go to original source... Go to PubMed...
  10. Halaska MJ, Komar M, Vlk R, et al. A pilot study on peak systolic velocity monitoring of fetal anemia after administration of chemotherapy during pregnancy. Eur J Obstet Gynecol Reprod Biol 2014; 174: 76-79. Go to original source... Go to PubMed...
  11. Cardonick E, Bhat A, Gilmandyar D, et al. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol.
  12. Ye X, He Q, Zhou X. Study on the adverse effects following chemotherapy for breast cancer diagnosis during pregnancy: The first case report in China. Medicine (Baltimore). 2017; 96(46): e8582. Go to original source... Go to PubMed...
  13. Wang ML, Dorer DJ, Fleming MP, Catlin EA. Clinical outcomes of near-term infants. Pediatrics 2004; 114(2): 372-376. Go to original source... Go to PubMed...
  14. Hibbard JU, Wilkins I, Sun L, et al. Respiratory morbidity in late preterm births. JAMA 2010; 304(4): 419-425. Go to original source... Go to PubMed...
  15. Shapiro-Mendoza CK, Lackritz EM. Epidemiology of late and moderate preterm birth. Semin Fetal Neonatal Med 2012; 17(3): 120-125. Go to original source... Go to PubMed...
  16. Smisek J, Plavka R. Výsledky péče o extrémně nezralé novorozence v České neonatologické síti, Čes-slov Pediat 2018; 73(1): 5-9.
  17. Sandall J, Tribe RM, Avery L, et al. Short-term and long-term effects of caesarean section on the health of women and children. Lancet. 2018; 392(10155): 1349-1357. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.